Markey's D'Orazio receives funding to further skin cancer research

August 10, 2015

LEXINGTON, Ky. (Aug. 10, 2015) - The University of Kentucky's Dr. John D'Orazio recently received grant funding totalling $375,000 over three years to further his research on melanoma, the deadliest form of skin cancer.

Three organizations provided an equal share of the funding: the Melanoma Research Alliance (MRA), the largest private funder of melanoma research; the Markey Cancer Foundation; and DanceBlue, the University of Kentucky's student-run fundraiser for pediatric cancer. Additionally, much of the preliminary data used in the MRA grant application was facilitated by pilot funding from the University of Kentucky's Center for Clinical and Translational Sciences.

D'Orazio's research focuses on the hormonal pathways that protect the skin from sun damage and how efficiently the skin's DNA may be able to repair itself. In a previous study, D'Orazio's team discovered a genetic defect in the melanocortin1 receptor (MC1R) leads to a reduced ability to repair DNA, making people more susceptible to developing melanoma.

The new project will focus on the specific hormones that appear to "turn off" MC1R signaling, also leading to an increased likelihood of developing the cancer.

Melanoma of the skin is one of the most common cancers in the United States and among the top 10 causes of new cancer cases. In the United States each year, more than 76,000 Americans are diagnosed with melanoma, and it is one of the most common cancers for young women. While the overall five-year survival rate for people diagnosed with melanoma is high at 92 percent, the survival rate decreases dramatically once melanoma spreads to other parts of the body.
-end-


University of Kentucky

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.